XPeng Backed HT Aero Unveils Flying Vehicle City Usage Scenarios
24.9.2021 08:58:00 EEST | Business Wire | Press release
HT Aero, an urban air mobility (UAM) company in which XPeng Inc. is an investor, today unveiled future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 ("X2"), including autonomous flight take-off and landing for specific city scenarios, back-end scheduling, charging and flight control.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923006034/en/
XPeng X2 flying vehicle (Photo: Business Wire)
XPeng X2 will present at the 13th Airshow China 2021, starting on September 28 in Zhuhai, Guangdong Province.
X2 is equipped with a robust, highly intelligent flight control system and superior autonomous flying capability, able to conduct autonomous flight route planning, all-round real-time imaging, real-time flight monitoring, two-way real-time communications, all-round environmental perception and autonomous return and landing. It is powered by a highly efficient and convenient charging system, leveraging XPeng’s supercharging technology.
The X2 has an user-friendly interface with one-key start, one-key return, and one-key landing, significantly reducing burdens for the user, delivering a safe and intelligent flight experience.
Before take-off, the system performs intelligent autonomous flight route planning based on the destination entered by the user, comprehensively evaluating factors such as surrounding buildings, no-fly and restricted areas, and weather conditions.
In a graphical recreational video, X2 demonstrates an efficient, effective and environmentally friendly commute from the top apron of a CBD building to a residential building, and connecting to the airport and other transportation hubs, simulating future lifestyle, business travel and other mobility scenarios.
In its first debut at an aerospace exhibition, X2 will be shown on September 28 at the 13th China International Aviation & Aerospace Exhibition (Airshow China 2021), showcasing its cutting-edge design and capabilities.
Introducing XPeng X2, the 5th generation flying vehicle
The XPeng X2 is the latest generation flying vehicle independently developed by HT Aero, having conducted more than 15,000 safe, manned flights. X2 is a pure electric two-seater enclosed-cockpit flying vehicle and an exploration of an aircraft-car integration with significantly improved effective load, passenger number, exterior design and flight control system than the previous generation.
X2 adopts a closed cockpit for the first time, with styling that shares the design language of the XPeng P7. It presents an elegant, minimalist and a teardrop profile. As well as its sci-fi appearance, X2 also takes into account high-efficiency aerodynamics to optimize flight performance.
With a full carbon fiber structure, X2 weighs 560 kilograms (empty aircraft with battery) and has the maximum take-off weight of 760 kilograms with a capacity of two passengers. It can cruise at a maximum design speed of 130 kilometers per hour and has a range of 35 minutes at a designed flying height of under 1,000 meters, suitable for low-altitude urban flight scenarios.
Powered purely by electricity, X2 has no carbon dioxide emissions during flight, in line with the company’s goal of green urban transportation. With 130 kilometers per hour, X2 can meet the needs of short-distance urban transportation, and can serve in scenarios such as air patrol, field rescue, and medical transportation.
About HT Aero
HT Aero aspires to be the leading pioneer of urban air mobility (UAM) and is dedicated to producing safe and intelligent electric flying vehicles which combine automotive and aerospace technologies to realize domestic air-travel usage at scale. Jointly funded and controlled by Mr. He Xiaopeng, XPeng Inc. and ZHAO Deli, HT Aero has a team of highly experienced R&D associates in multiple disciplines such as avionics, test flight, airworthiness, safety, structural mechanics, industrial design and embedded systems. Established in 2013, it has accumulated 15,000 safe, manned flight experiences. For more information, please visit https://www.aeroht.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923006034/en/
Contact information
Marie Cheung
mariecheung@xiaopeng.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
